Kyle Carver Sells 18,175 Shares of Evommune (NYSE:EVMN) Stock

Posted by Brian Himes on Jun 1st, 2026

Evommune, Inc. (NYSE:EVMN – Get Free Report) CFO Kyle Carver sold 18,175 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $22.84, for a total value of $415,117.00. Following the transaction, the chief financial officer owned 59,335 shares of the company’s stock, valued at approximately $1,355,211.40. This represents a 23.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Evommune Trading Down 5.1%

Shares of NYSE EVMN traded down $1.20 during mid-day trading on Monday, reaching $22.04. 451,405 shares of the company’s stock were exchanged, compared to its average volume of 416,057. Evommune, Inc. has a 52-week low of $13.89 and a 52-week high of $33.20. The stock’s 50-day moving average is $24.14.

Evommune (NYSE:EVMN – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. Research analysts predict that Evommune, Inc. will post -2.83 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on EVMN shares. Weiss Ratings started coverage on Evommune in a report on Tuesday, February 3rd. They set a “sell (e)” rating for the company. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Evommune in a report on Tuesday, May 26th. Morgan Stanley raised their target price on Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Oppenheimer started coverage on Evommune in a report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 target price for the company. Finally, Evercore restated an “outperform” rating and set a $55.00 target price on shares of Evommune in a report on Tuesday, February 10th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Evommune has an average rating of “Buy” and an average target price of $49.25.

View Our Latest Research Report on EVMN

Institutional Investors Weigh In On Evommune

Hedge funds and other institutional investors have recently made changes to their positions in the business. Strs Ohio acquired a new stake in shares of Evommune during the 1st quarter worth about $41,000. China Universal Asset Management Co. Ltd. purchased a new position in Evommune during the 4th quarter worth approximately $34,000. The Manufacturers Life Insurance Company purchased a new position in Evommune during the 4th quarter worth approximately $179,000. XTX Topco Ltd purchased a new position in Evommune during the 4th quarter worth approximately $321,000. Finally, Oxford Asset Management LLP purchased a new position in Evommune during the 4th quarter worth approximately $335,000.

About Evommune

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.